Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

41 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Elucidation of the mechanism behind the potentiating activity of baicalin against Burkholderia cepacia complex biofilms

ABSTRACT: Burkholderia cenocepacia J2315 biofilms were described to have an increased susceptibility towards tobramycin when baicalin hydrate was added to the treatment. The goal of this transcriptomic analysis is to elucidate the effect of baicalin hydrate on gene expression levels when added to tobramycin treatment. Therefore, biofilms were grown for 24 hours and treated for another 24 hours with either tobramycin (TOB) (1024ug/ml), baicalin hydrate (BH) (250uM) or a combination of both. Also, an untreated control (physiological saline) was included. This experiment was repeated twice, so three biological replicates per treatment were included for RNAsequencing.

INSTRUMENT(S): NextSeq 500

ORGANISM(S): Burkholderia cenocepacia

SUBMITTER: Lisa Slachmuylders

PROVIDER: E-MTAB-6099 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Sessile burkholderia cepacia complex cells survive antibiotic treatment by avoiding production of reactive oxygen species

Project description:In the present study we wanted to investigate the molecular mechanisms responsible for the tobramycin tolerance in Burkholderia cenocepacia J2315 biofilms.

2012-02-01 | E-MEXP-3532 | biostudies-arrayexpress

Transcription profiling of P. aeruginosa biofilms treated with tobramycin grown on CFBE41o- cells

Project description:We grew Pseudomonas aeruginosa biofilms on CFBE41o- human airway cells in culture, and we treated these biofilms with tobramycin. Microarray analysis was performed to gain an understanding of the global transcriptional changes that occur during antibiotic treatment. Experiment Overall Design: We compared three untreated control samples with three tobramycin-treated samples. Biofilms were grown on CFBE41o- cells in culture for 9 hours in MEM/0.4% arginine. Replicate samples were then incubated in the presence or absence of 500 Î¼g/mL tobramycin for 30 minutes.

2008-06-18 | E-GEOD-9989 | biostudies-arrayexpress

Transcription profiling of Pseudomonas aeruginosa treated with tobramycin

Project description:This SuperSeries is composed of the following subset Series:; GSE9989: Tobramycin Treatment of P. aeruginosa Biofilms Grown on CFBE41o- Cells; GSE9991: Tobramycin Treatment of Planktonic Pseudomonas aeruginosa Experiment Overall Design: Refer to individual Series

2008-06-18 | E-GEOD-10030 | biostudies-arrayexpress

Transcription profiling of planktonic pseudomonas aeruginosa exposed to tobramycin treatment

Project description:As a comparison to tobramycin-treated P. aeruginosa biofilms, we investigated the response of planktonic P. aeruginosa to tobramycin by microarray. Experiment Overall Design: We included 2 control (untreated) cultures and 2 tobramycin-treated cultures. We used mid-exponential phase cultures of P. aeruginosa PA14. Replicate cultures were incubated in the presence or absence of 5 Î¼g/mL tobramycin for 30 minutes at 37Â°C.

2008-06-21 | E-GEOD-9991 | biostudies-arrayexpress

Experimental evolution of Pseudomonas aeruginosa biofilms exposed to furanone C-30 with and without tobramycin

Project description:The aim of this study is to evaluate the evolutionary robustness of the quorum sensing inhibitor (QSI) furanone C-30 for the treatment of P. aeruginosa biofilm infections. We repeatedly exposed P. aeruginosa biofilms to furanone C-30 (with or without tobramycin) in the synthetic cystic fibrosis sputum medium (SCFM2) and characterized the genotype and phenotype of the evolved lineages. P. aeruginosa biofilms were grown in SCFM2 for 24 h after which the treatment in fresh SCFM2 was added to obtain a final concentration of 20 µg/ml tobramycin and 100 µg/ml furanone C-30. The negative control was treated with fresh SCFM2, including the same amount of DMSO (0.25%) as for the biofilms treated with C-30. After 24 h of static incubation at 37°C, biofilms were sonicated and vortexed in order to disintegrate the biofilm aggregates. After each cycle the number of CFU was determined and an aliquot of the culture was stored at -80°C in Microbank vials to allow further tests on the evolved strains. A sample from the treated biofilm was used to prepare a new overnight culture, in order to start a new cycle. For each treatment three independent lineages were established, that were each exposed for 16 cycles. Whole-genome sequencing was performed on the wild type P. aeruginosa PAO1 and on the exposed lineages after 5, 10 and 16 cycles.

2021-03-05 | E-MTAB-10124 | biostudies-arrayexpress

Identification of genes involved with P. aeruginosa biofilm antibiotic resistance by microarray analysis

Project description:Microarray analysis was used to identify changes in the level of transcription of genes in P. aeruginosa drip flow biofilms in response to ciprofloxacin and tobramycin exposure. This data was evaluated and used to select strains that carry transposon mutations in genes that might play a role in antibiotic tolerance of biofilms. The strains were evaluated for defects in biofilm tolerance. Four drip flow biofilm conditions with three replicates each: (1) baseline controls at 72 hours, (2) tobramycin treated for 12 hours past baseline, (3) ciprofloxacin treated for 12 hrs past baseline, and (4) no treatment for 12 hrs past baseline.

2015-05-11 | E-GEOD-65870 | biostudies-arrayexpress

Various evolutionary trajectories lead to loss of activity of tobramycin-potentiating compounds in Burkholderia cenocepacia biofilms

Project description:Antibiotic adjuvants are commonly described as an alternative approach to overcome bacterial resistance towards conventional antibiotics. In this experiment, we investigated this statement for tobramycin (TOB) in combination with three adjuvants; baicalin hydrate (BH), a quorum sensing inhibitor, econazole (ECO) and miconazole (MICO), two antifungal agents that are repurposed as antibiotic adjuvants. We repeatedly exposed mature (24 hour old) Burkholderia cenocepacia J2315 biofilm cells to TOB alone (768ug/ml), or a combination of TOB with either BH (250uM), ECO (1uM) or MICO (1uM). We also included an untreated control. After a treatment, the remaining cells were quantified and the cells were allowed to regrow for another 48 hours. This process is one cycle. At the end of the experiment, biofilm cells were exposed to 15 cycles. DNA extraction was performed on the evolved cells and of cells from the start population. DNA sequencing was performed on these samples and single nucleotide polymorphisms compared to the start population were evaluated.

2018-07-22 | E-MTAB-6236 | biostudies-arrayexpress

Kristen-PAO1 aerobic sub-inhibitory cond. tobramycin

Project description:To see the effect of sub-inhibitory concentrations of tobramycin on Pseudomonas aeruginosa grown under aerobic conditions. RNA was isolated form 4 biological repeats of P.aeruginosa grown to mid-log in cationic adjusted mueller hinton broth and 4 biological repeats of P.aeruginosa with the addition of 0.25ug/ml tobramycin in cationic adjusted mueller hinton broth. null

2011-03-30 | E-FPMI-23 | biostudies-arrayexpress

Kristen-PAO1-aerobic PA0779

Project description:To see the effect of lethal contrations of tobramycin under aerobic conditions in PAO1::PA0779 . RNA was isolated from 3 biological repeats of PAO1::PA0779 grown to mid-log in cationic adjusted meuller hinton broth containing 15mM KNO3, and 3 biological repeats of PAO1::PA0779 to which 2 ug/ml tobramycin was added after cells reached mid-log.

2011-01-20 | E-FPMI-27 | biostudies-arrayexpress

Kristen-PAO1-anaerobic lethal concentrations tobramycin

Project description:To see the effects of tobramycin on Pseudomonas aeruginosa under anaerboc lethal conditions. RNA was isolated from 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 and 5 biological repeats of P.aeruginosa grown in cationic adjusted mueller hinton broth containing 15mM KNO3 after being treated with 20 ug/ml tobramycin for 30 minutes.

2011-01-20 | E-FPMI-24 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data